Regeneron has said it has begun clinical trials of its antibody cocktail therapy for COVID-19, as pharma companies continue their search for treatments as the pandemic continues to cause havoc ...

Scientists from Regeneron selected the two most potent, non-competing virus-neutralising antibodies and scaled up production to create the REGN-COV2 cocktail. REGN-COV2's two antibodies bind ...

What lessons can be learnt from treating Trump? Why is his proclamation of Regeneron's unproven and experimental antibody cocktail so dangerous? What is commission bias? With some updates about ...

The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody ...

Regeneron has leveraged its monoclonal antibody ... yet a windfall from sales of its covid antibody cocktail as well as continuing solid sales of Eylea and Dupixent still gave the firm more ...

Regeneron’s Lynozyfic is a bispecific antibody that works by bridging B-cell maturation antigen on MM cells with CD3-expressing T cells to drive T-cell activation and cancer-cell killing. The drug can ...

Regeneron has since re-filed the BCMAxCD3 drug in the U.S., and it's now awaiting a July 10 decision target date. With linvoseltamab's delayed arrival in the U.S., the multiple myeloma bispecific ...

Regeneron’s investigational BCMAxCD3 bispecific antibody. These include combinations of linvoseltamab with carfilzomib or bortezomib in relapsed/refractory (R/R) multiple myeloma (MM ...

The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic (linvoseltamab) for adults with relapsed and refractory (R/R ...